Castle Biosciences, Inc.
NASDAQ:CSTL
Overview | Financials
Company Name | Castle Biosciences, Inc. |
Symbol | CSTL |
Currency | USD |
Price | 32.72 |
Market Cap | 916,398,856 |
Dividend Yield | 0% |
52-week-range | 16.965 - 35.84 |
Industry | Diagnostics & Research |
Sector | Healthcare |
CEO | Mr. Derek J. Maetzold |
Website | https://castlebiosciences.com |
An error occurred while fetching data.
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD